Friday, April 3, 2026
30.4
C
Bengaluru
Hot topics
Zaynich and the $9 Billion Moment: A New Dawn for Indian Pharma?
A quiet but revolutionary milestone may be unfolding in...
Indian Pharma CEO Roundtable 2023
Theme: India Pharma’s Digital Journey – The Progesss from...
MedicinMan Indian Pharma Digital Adoption Survey
Smaller Indian pharma companies bore the strongest impact from...
IMS Health Market Reflection Report for September 2016
The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.
Managed Healthcare – Better Choice for India?
Managed care shifts healthcare from fragmented fee-for-service models to...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hot topics
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
How Did Telma Become a 1000+ Cr Brand?
The untold story of Glenmark's phenomenal success in building...
How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies
April 14, 2025
India’s pharmaceutical industry, a global powerhouse, sends...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
Newsletter
Get important news delivered directly to your inbox and stay connected!